JADE-001

March 6, 2026: Jade Biosciences, Inc. (NASDAQ: JBIO) reported Q4/full-year 2025 financial results and outlined upcoming clinical catalysts across its autoimmune pipeline.

JADE101 (selective anti-APRIL mAb; IgA nephropathy): Ongoing Phase 1 healthy volunteer study; biomarker-rich interim data expected in Q2 2026 to inform dose and dosing interval for IgAN studies. The company expects to start a Phase 2 trial in IgA nephropathy in mid-2026, with preliminary data anticipated in 2027.

JADE201 (half-life extended, afucosylated anti-BAFF-R mAb; autoimmune diseases): First-in-human clinical trial in rheumatoid arthritis patients expected to begin in Q2 2026; interim data anticipated in 2027.

JADE301 (undisclosed antibody program; autoimmune diseases): Development candidate nominated; Phase 1 first-in-human trial expected to commence in the first half of 2027, with additional program details expected in the second half of 2026.

Financials: Cash, cash equivalents and investments of $336.2M as of Dec. 31, 2025; runway expected into the first half of 2028. Q4 2025 net loss was $31.9M; full-year 2025 net loss was $127.4M. The company also completed two private placements in Q4 totaling ~$180M gross proceeds.